Immunitybio receives fda rmat designation for anktiva® and car-nk for the reversal of lymphopenia in patients receiving standard-of-care chemotherapy/radiotherapy and in treatment of multiply relapsed locally advanced or metastatic pancreatic cancer

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a leading immunotherapy company, today announced the u.s. food and drug administration (fda) has granted regenerative medicine advanced therapy (rmat) designation for anktiva® and car-nk (pd-l1 t-hank) for the reversal of lymphopenia in patients receiving standard-of-care chemotherapy/radiotherapy and in multiply relapsed locally advanced or metastatic pancreatic cancer. the complete blood count (cbc) is a standard assay wi.
IBRX Ratings Summary
IBRX Quant Ranking